$HCM

$13.14▲ -3.7% YTD

9 SEC 13D/G filings tracked · Last updated Nov 2, 2026

Filing History

CP $13.14▲ -3.7%Nov 2, 2026 · ThinkSabio Blog

$HCM - HUTCHMED Announces Regulatory Filings Accepted for Review for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer in Europe and Jap…

News

HCM ▼ -3.5% - HUTCHMED (China) Limited

CP $13.32▲ -3.5%Oct 29, 2026 · ThinkSabio Blog

$HCM - HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia…

News

HCM ▼ -1.0% - HUTCHMED (China) Limited

CP $14.27▲ -1.0%Oct 27, 2026 · ThinkSabio Blog

$HCM - Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer…

News

HCM ▲ +0.6% - HUTCHMED (China) Limited

CP $14.50▲ +0.6%Oct 26, 2026 · ThinkSabio Blog

$HCM - HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026…

News

HCM ▲ +0.6% - HUTCHMED (China) Limited

CP $14.36▲ +0.6%Oct 26, 2026 · ThinkSabio Blog

$HCM - HUTCHMED Highlights SAFFRON Global Phase III Data Presented at ESMO Congress 2026 and Simultaneously Published in The New England Journal of Me…

News

HCM ▲ +3.9% - HUTCHMED (China) Limited

CP $14.74▲ +3.9%Oct 21, 2026 · ThinkSabio Blog

$HCM - HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China…

News

HCM ▲ +0.9% - HUTCHMED (China) Limited

CP $14.13▲ +0.9%Sep 29, 2026 · ThinkSabio Blog

$HCM - HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer…

News

HCM ▲ +2.1% - HUTCHMED (China) Limited

CP $14.37▲ +2.1%Sep 24, 2026 · ThinkSabio Blog

$HCM - HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026…

News

HCM ▲ +1.1% - HUTCHMED (China) Limited

CP $12.04▲ +1.1%Sep 3, 2026 · ThinkSabio Blog

$HCM - HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy…